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SHORT TITLE: Meta-analysis: risk of CVA with atypical antipsychotics use 
 
ABSTRACT: 
Background: Second-generation (atypical) antipsychotics are often prescribed in 
the treatment of Behavioral and Psychological Symptoms of Dementia (BPSD), 
however, their use has been discouraged in light of clinical trials suggesting that 
they cause an increased risk of cerebrovascular accidents (CVA).  
  
OBJECTIVE: Aim of the study was to assess relative risk of CVA in dementia patients 
prescribed second-generation (atypical) antipsychotics rather than first-generation 
(typical) antipsychotics,  through meta-analysis of population-based studies.  
 
METHODS: A literature search was conducted using several relevant databases. 
Five studies were included in the review and data were pooled to conduct meta-
analysis using the inverse variance method. 
 
RESULTS: Amongst a total of 79910 patients treated with SGAs, including 
risperidone, quetiapine and olanzapine, and a total number of 1287 cases of CVA 
were reported. In the comparison group, which consisted of 48135 patients treated 
with FGAs, a total of 511 cases of CVA were reported. The relative risk (RR) of CVA 
was 1.02 (95% CI, 0.56-1.84) for the SGA group. There was no significant difference 
in the risk of stroke (p < 001) between groups, but significant heterogeneity was 
found among the results of included studies (p < 0.001). 
 
CONCLUSION: Meta-analysis of population-based data suggest that the use of 
second-generation as opposed to first-generation antipsychotics to control BPSD is 
not associated with significantly increased risk of CVA . Despite the large numbers 
of participants, only four studies were included in this meta-analysis, and our 
results are therefore best interpreted as suggestive of no difference in risk between 
the two classes of antipsychotic, rather furthering a definitive conclusion to this 
effect.   
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Dementia is a clinical syndrome of deterioration in cognitive function, which 
goes beyond what would be expected from normal aging and is associated with 
impairment in a person’s everyday functioning1. It affects 6% to 8% of adults over 
65 years of age and approximately 20% of adults over the age of 802. Dementia 
imposes a considerable emotional and physical challenge for patients and their 
families3. Irrespective of the underlying pathology, the syndrome necessitates a 
multifaceted management approach5. Pharmaceutical interventions form part of 
this, and are the focus of this review.  Acetylcholinesterase (AchE) inhibitors, 
namely donezapil, rivastigmine and galantamine, are currently recommended in the 
UK to improve cognitive function in mild to moderate Alzheimer’s disease, while the 
N-methyl-d-aspartate (NMDA) receptor antagonist, memantine, is recommended for 
patients unable to tolerate AChE inhibitors or for the same indication in severe 
Alzheimer’s disease5.  However, addressing non-cognitive symptoms such as 
agitation, anxiety, delusions, hallucinations and associated aggressive behavior 
forms a substantial component of the global management of dementia6. These 
symptoms, commonly termed Behavioral and Psychological Symptoms of Dementia 
(BPSD), occur with high frequency, particularly in Alzheimer’s disease, where their 
estimated prevalence is as high as 90%. BPSD also present a major challenge for 
those who provide care for people with dementia6. 
Non-pharmacological interventions, such as treating undetected sources of 
pain or improving the patient’s environment, remain first line management for both 
acute and chronic BPSD7. Antipsychotic medication is recommended by NICE 
(National Institute for Health and Care Excellence) only if the patient remains in 
severe distress despite these interventions, and/or poses a risk of harm to 
themselves or others. Indeed, the Banerjee Report, an independent review of the use 
of antipsychotics in elderly people with dementia commissioned by the UK 
government, concluded that antipsychotics were overused to treat BPSD, given the 
associated risks of these drugs and their relatively limited clinical benefit8. In this 
review we focus on the increased risk of cerebrovascular accident (CVA) which has 
been associated in particular with the prescribing of second-generation 
antipsychotics (SGAs, also known as atypical antipsychotics) for people with 
dementia. This risk came to light following a series of clinical trials from 2002 
onwards9,10.  
A recent Cochrane review based on five randomized controlled trials of SGA 
use in Alzheimer’s disease (also incorporating data published by the Committee for 
the Safety of Medicines) found that patients treated with risperidone were 
significantly more likely than placebo-treated controls to experience serious 
adverse cerebrovascular events (37/1175 vs 8/779, OR 3.64, 95% CI 1.72 to 7.69, P 
= 0.0007)8. However, the Cochrane review did not comment on CVA risk associated 
with other second-generation drugs, nor were individuals prescribed SGAs directly 
compared with those prescribed the older, first-generation antipsychotics (FGAs, 
also known as typical antipsychotics) to assess their relative risk of CVA.  
Population-based administrative data has become an advantageous 
alternative tool for research of clinical outcomes11. It is primarily collected for 
billing purposes from providers and in many countries is gathered on a national 
scale12. Such data includes a large number of patients with relevant clinical 
indicators. Administrative data has recently been used to directly compare risk of 
CVA between risperidone, a SGA, and other antipsychotics13. Here we aim to 
establish the excess CVA risk associated with SGA, as compared to FGA by 




PRISMA guidelines were followed to conduct the systematic review6. The following 
inclusion criteria were used: 
1. Participants: population over the age of 60. 
2. Intervention: individuals treated with only one class of antipsychotic, giving 
rise to FGA and SGA groups.  
3. Method: Direct comparison of FGA and SGA groups with CVA as one of the 
outcomes of the study.  
4. Outcome: incidence of any type of CVA among participants. 
5. Study design: studies based on retrospective population-based 
administrative data to assess risk or incidence of any type of cerebrovascular 
accident (CVA) in dementia patients.  
 
The following exclusion criteria were used: 
1. Studies that used clinical data from controlled trials, local hospitals or single-
centres, and case series.  
2. Studies that evaluated the use of antipsychotics and risk of CVA in 
populations diagnosed with medical conditions other than dementia.  
Search and study selection 
The literature search was conducted from 15th March to 15th May 2015. The 
following literature databases were used: Embase (1947-2015), Medline (1946-
2015), Web of Science (1950-2015), Current Contents Connect, SciELO citation 
index. Various search terms were used to identify studies that discussed risk of CVA 
in patients with the use of antipsychotics (Table 1). Search terms for stroke, 
dementia and antipsychotics were ‘exploded’ to include all relevant terms. All the 
subheadings were included in the search. Similarly, ‘$’ was used to include both 
singular and plural forms of the search term. Boolean terms, such as ‘AND’ and ‘OR’, 
were used to combine search terms to search for relevant titles. Further studies 
were identified through cross-referencing of studies reviewed initially. Two 
independent researchers, AR and AS, reviewed the selected studies separately.  
Data collection 
The data was collected from 01 May 2015 to 30th May 2015 by Authors AR 
and AS independently. The following information was extracted from the included 
studies: primary authors, year of publication, the place where study was conducted, 
administrative database used, type of CVA, follow-up period, duration of exposure of 
anti-psychotics, number of patients in each group, types of antipsychotics used, and 
incidence of CVA in each group.  
Assessment of bias 
The Newcastle-Ottawa scale was used to assess bias in the studies14. The 
scale uses star ranking based on thee major criteria: selection of participants, 
comparability and definition of outcome. A maximum of eight star ranking can be 
obtained by a study. The scale has been validated and recommended by Cochrane 
review methodological guidelines for non-randomised cohort studies.  
Statistical methods 
           Statistical software Review Manager, version 5.3 (The Cochrane Collaboration, 
Software Update, Oxford, United Kingdom) was used to perform the analysis14. The 
Risk Ratio (RR) was used to analyse differences in dichotomous variables, and 95% 
confidence intervals (CI) were reported for each derived statistic. An inverse-
variance method of meta-analysis was used, since this method assigns more weight 
to studies with larger cohorts and smaller standard errors, than to those with small 
groups of patients and large standard errors. This method was used within a 
random-effect model so that it can evaluate any heterogeneity between the studies.  
We illustrated the relative strength of treatment effects using a forest plot14, 
where the measure of the treatment effect for each study is shown in terms of the 
odds ratio for categorical variables, with horizontal lines showing confidence 
intervals. The overall treatment effect is shown as a diamond. The vertical line in the 
graph is the line of no effect. If the confidence interval horizontal line of a particular 
study overlaps this line, then the size of the treatment effect of the individual study 
is not significant (no-effect). Similarly, if the lateral points of the diamond, indicating 
the overall effect, intersect the vertical line of no effect, there is no difference 
between overall treatment sizes of the two groups. The chi-squared test 
(was included in the forest plot to assess heterogeneity of intervention’s 
effect, that is variation in the outcome beyond chance. Inconsistency across the 
studies was quantified by I2 method.  
We also used a funnel plot, in which the individual treatment effect of each 
study is plotted against its study size, to illustrate the extent of publication bias14. A 
symmetrical funnel shape of the scattered plot of studies is likely to indicate no 
publication bias, heterogeneity between studies, and a “small study effect”, where 

















Characteristics of studies 
The search strategy for the selection of studies was based on the PRISMA 
protocol for the conduction of systematic reviews (figure 1).  Initially, 648, 690 titles 
were identified from the search, however this number was reduced to 565 when the 
terms were combined together with Boolean terms and duplicate titles excluded. On 
screening of the titles, 55 were considered relevant and had their abstracts 
reviewed. In total, 16 full-text articles were reviewed, and five studies were included 
in the meta-analysis based on the inclusion criteria mentioned above. Excluded 
studies with their reasons for exclusion from the review are outlined in Table 2.  
A total of five studies were included in the review, most of which were 
conducted in US and Canada (Table 3). All studies identified two cohorts of patients: 
dementia patients prescribed FGAs and dementia patients prescribed SGAs. Two 
studies had additional control groups: patients not taking any antipsychotics15 and 
patients taking benzodiazepines13. The follow-up duration ranged from 3 months to 
5 years. Most studies included all elderly patients over the age of 65 using 
antipsychotics, while two studies only focused on patients with confirmed diagnosis 
of dementia13, 15.  
Risk of CVA with the use of SGAs 
Four studies did not find any significant difference between patients treated 
with second- and first-generation antipsychotics. However, in one study, the risk of 
CVA was higher with the use of FGAs (haloperidol and prochlormazine) as 
compared to SGA (risperidone). Cerebrovascular accidents included all types of 
haemorrhagic stroke (subarachnoid, intracerebral or cranial haemorrhage) and 
ischaemic stroke (cerebral occlusion, stenosis, or thrombosis) as well as other 
cerebrovascular events like transient ischaemic attack, cerebral artery spasm and 
ill-defined cerebrovascular disease, however, Gill et al and Shin et al only included 
incidence of ischaemic stroke outcomes.  
Barnett et al examined risk of inpatient admission for CVA associated with 
antipsychotic prescribing in 14029 adults over the age of 65 receiving care for 
dementia, using patient information from the Veterans Administration (VA) and 
Medicare Provider and Analysis Review Part A (MEDPAR-A) data files. Slightly over 
a quarter of their sample (27%, n = 3725) were diagnosed with vascular-type 
dementia, while the remaining 73% (n = 10,304) had a diagnosis of Alzheimer’s 
dementia. Amongst those prescribed anitpsychotics, a larger proportion (n=1585) 
had been newly prescribed second-generation drugs, including risperidone (5.8%), 
quetiapine (2.9%) and olanzapine (2.5%), whereas only 1.3% of the sample (187) 
were found to be newly started on an FGA, of which haloperidol formed the largest 
component (1.2%). On average, patients received olanzapine, risperidone and 
quetiapine for 116.4 +/- 126.2, 107.9 +/- 112.9 and 128.1 +/- 127.3 days 
respectively, compared to haloperidol (79.6 +/- 99.6 days). 
The authors showed that the risk of admission for CVA was not significantly 
raised in patients treated with antipsychotics,  whether second-generation (n=1585, 
relative risk [RR]=1.20; 95% CI, 0.83-1.73) or first-generation (n=187, RR=1.29; 
95% CI, 0.48-3.47), as compared to those not receiving antipsychotics (n=12257)15. 
In an analysis of all subtypes of dementia, the authors found no significant 
difference in the risk of CVA between individual SGAs (risperidone [RR=0.49; 95% 
CI, 0.21-1.12], olanzapine [RR=0.62; 95% CI, 0.25-1.53], quetiapine [RR=0.70; 95% 
CI, 0.30-1.65]) and haloperidol. However, in a subgroup analysis of the patients with 
vascular dementia, the risk of CVA was higher with the use of either SGAs (RR=1.47; 
95% CI, 0.76-2.84) and FGAs (RR=2.57; 95% CI, 0.60-11.06) compared to no use of 
antipsychotics. In the vascular subgroup however, the authors note a significantly 
decreased risk of CVA in patients receiving risperidone, relative to those prescribed 
haloperidol (RR=0.13; 95% CI, 0.03-0.63). 
                    In an analysis of Medicaid data, Finkel et al compared the risk of inpatient 
admission for CVA in patients over the age of 60 who were receiving treatment for 
dementia, and who had been newly prescribed either SGAs (n=8285), FGAs 
(n=1260) or benzodiazepines (n=9442), following a period of six months or more of 
no use of these medicines13. The authors adopted benzodiazepines as a control 
group since benzodiazepines are among the most widely used non-antipsychotic 
treatments for BPSD. The FGA group in this study only included patients prescribed 
haloperidol, which the authors justified on the basis that haloperidol use 
represented 80% of the FGA prescribing within the cohort. The patients were 
followed up for maximum of 3 months after the initiation of antipsychotic or until 
the event of acute inpatient admission with stroke.  
  In the first multivariate analysis, the authors compared the risk of CVA for a 
reference group prescribed risperidone (n=4137) with CVA risk for patients 
prescribed olanzapine (n=2928), quetiapine (n=710), haloperidol (typical anti-
psychotic [n=1260]) or benzodiazepines (n=9442). No significant difference in the 
incidence of CVA was found between risperidone and either olanzapine or 
quetiapine. However, haloperidol (P<0.05) and benzodiazepines (P<0.001) were 
associated with significantly greater odds of CVA than risperidone. In a second 
multivariate analysis, benzodiazepines were taken as a reference group. All SGAs 
(P<0.001), olanzapine (P<0.005), risperidone (P<0.001) and quetiapine (P<0.05) 
had significantly lower odds of CVA than benzodiazepines. The authors depicted 
odds ratios graphically and their numeric values were not stated in the study text.  
Vasilyeva et al examined administrative health care database in Manitoba, 
Canada to compare CVA risk in patients over the age of 65 prescribed SGAs 
(n=7779) with that associated with FGAs (n=4655)17. The most common SGA was 
risperidone (66.6%) followed by olanzapine (22.5%) and quetiapine (11%). 
Common FGAs were prochlorperazine (52.7%) followed by haloperidol (19.9%), 
methotrimeprazine (9%), loxapine (7.7%), and chlorpromazine (6.9%). Patients 
were followed up until the occurrence of cerebrovascular event and maximum upto 
1 year. The cummulative incidence of all SGAs were compared with FGAs. The total 
incidence of stroke was 809 and 197 in SGAs and FGAs respectively. There was no 
significant difference in the incidences of stroke between the groups. The hazard 
ratio (HR) was 1.136 (CI 0.961-1.344).  
Gill et al examined administrative healthcare databases in Ontario, Canada, 
so as to compare two cohorts of adults over aged 65 with dementia: those who had 
been newly prescribed SGAs (risperidone, olanzapine, and quetiapine) and those 
who had been newly prescribed FGAs (haloperidol, fluphenazine, thiothixene, 
pimozide, trifluoperazine, flupenthixol, zuclopenthixol, thioproperazine, 
chlorpromazine, thioridazine, mesoridazine, loxapine, perphenazine, promazine, 
pericyazine, and chlorprothixane). Their primary outcome of interest was hospital 
admission with a primary diagnosis of ischaemic stroke. Patients were observed for 
at least 30 days after they were prescribed antipsychotics. The follow-up period 
lasted for maximum of 4 years and ended with the events of stroke, death, switch to 
another antipsychotic or discontinuation of medication. The authors found an 
incidence of ischaemic stroke of 284 amongst patients prescribed SGAs (n=17,845), 
by comparison to 227 in  the FGA group (n=14,865)16, amounting to a non-
significant difference in relative risk (1.01, 95% CI, 0.81-1.26). Similarly, the risk of 
stroke amongst patients prescribed risperidone (adjusted hazard ratio [HR] 1.04; 
95% CI, 0.82-1.31), olanzapine (HR 0.91; 95% CI, 0.62-1.32) or quetiapine (HR 0.78; 
95% CI, 0.38-1.57) was not significantly greater than that amongst those prescribed 
FGAs.  
Shin et al examined administrative healthcare databases in Korea, so as to 
compare two cohorts of adults over aged 65: those who had been newly prescribed 
SGAs and FGAs. The patients on SGAs were prescribed risperidone (n=24668), 
quetiapine (n=15860), and olanzapine (n=3888), whereas patients on FGAs were 
prescribed haloperidol (n=19564) and chlorpromazine (n=7604). Their primary 
outcome of interest was hospital admission with a primary diagnosis of ischaemic 
stroke. Patients were observed for maximum period of 3 years after they were 
prescribed antipsychotics. The follow-up period ended with the events of stroke, 
death, switch to another antipsychotic or discontinuation of medication. The 
average follow-up period was 150.9 days (SD 172.6) and 130.3 days for SGAs and 
FGAs respectively. Overall, the incidence rate was 62 and 64 for SGAs (n=44416) 
and FGAs (n=27168) respectively. The incidence of stroke was specific 
antipsychotics were as following: risperidone (n=31/24668), quetiapine 
(n=36/15860), olanzapine (n=5/3888), haloperidol (n=43/19564), and 
chlorpromazine (n=21/7604). There was higher risk of stroke associated with FGAs 
compared to SGAs (adjusted HR 2.71; 95% CI, 2.01-3.52). Similarly, the risk of 
stroke in patients prescribed haloperidol (adjusted HR 2.64; 95% CI, 1.27-3.26) and 
chlorpromazine (adjusted HR 3.50; 95% CI, 2.17-5.65) compared to risperidone.  
 
Meta-analysis 
Amongst a total of 79910 patients treated with SGAs, including risperidone, 
quetiapine and olanzapine, and a total number of 1287 cases of CVA were reported. 
In the comparison group, which consisted of 48135 patients treated with FGAs, a 
total of 511 cases of CVA were reported. The relative risk (RR) of CVA was 1.02 
(95% CI, 0.56-1.84) for the SGA group. There was no significant difference in the 
risk of stroke (p 0.96), however, this was associated with significant heterogeneity 
among the results of included studies (p < 0.001) (Figure 2).  
Two studies also compared risk of CVA in dementia patients using SGAs with 
those not taking any antipsychotics13, 15. The incidence of CVA in those prescribed an 
SGA was 126/9870 as compared to those not taking any antipsychotics 
(n=493/21699). The relative risk (RR) of CVA was 0.95 (95% CI, 0.78-1.17) for the 
atypical antipsychotic group, which was not significantly different from non-users 
(p= 0.66) with non-significant heterogeneity between the studies (p= 0.21).  
 Risk of publication bias 
All studies included in the review had a rating of 5 or above on the NOS scale 
indicating that each study was deemed to have a low risk of bias due to the selection 
of patients, adequate follow-up and clearly defined outcome measures, and that the 
comparison groups were adequately matched for co-morbidities and social 


















The results from the meta-analysis conducted on five studies using 
population administrative data find no significant difference in the rate of CVA 
amongst dementia patients prescribed newer second-generation (atypical) anti-
psychotics as compared to those receiving older, first-generation (typical) anti-
psychotics.  
A biological explanation for the link between CVA and use of anti-psychotic 
medication remains obscure16. Antipsychotics, in particular the second-generation 
drugs, have been linked to changes in the metabolism of lipids and glucose, 
however, these changes are likely to manifest over a long timescale and would not 
appear to explain why most CVA events occur within 6-12 weeks of commencing 
medication. A further possibility is that the high risk of CVA may be related to the 
anti-cholinergic properties of first-generation antipsychotics,  resulting in 
hypotension, changes in heart rate and blood pressure, which in turn cause 
microinfarcts in the brain21. Paradoxically however, the use of risperidone, a 
second-generation antipsychotic, is associated with inhibition of platelet 
aggregation, which is most likely to cause decreased risk of ischaemic stroke16 
Our meta-analysis suggested that there was significant heterogeneity 
between the studies to account for any risk of CVA associated with type of 
antipsychotics. Three studies included in the review did not find significant risk of 
CVA associated with SGAs compared to FGAs13, 15, 16. Vasilyeva et al. demonstrated 
higher incidence rate of CVA in SGAs group but the risk was similar to FGAs when 
adjusted for patients’ characteristics and past medical history29.  On the other hand, 
the risk of CVA was significantly higher in FGAs group (haloperidol and 
chlorpromazine) as compared to SGAs (risperidone)9. Two studies included in the 
review also compared risk of CVA in patients prescribed second-generation 
antipsychotics to those not taking any antipsychotics13, 15. The analysis from these 
studies found that use of a second-generation antipsychotic did not significantly 
increase risk of CVA relative to the non-user group. On the other hand, previous 
clinical trials have found that risperidone was associated with increased risk of CVA 
as compared to a placebo group. However, these trials did not comprehensively 
assess the risk of CVA associated with the use of other second-generation 
antipsychotics in dementia patients13,17. Nor did they take into account confounding 
risk factors that could contribute to increased risk of CVA, such as previous stroke, 
diabetes, hypertension, atrial fibrillation and hyperlipidaemia. Furthermore these 
studies had a short follow-up period and did not show any significant difference in 
other serious medical events (drug reaction, hospitalisation, disability, and death) 
between second-generation antipsychotics and placebo13. After the published data 
from the clinical trials, the use of second-generation antipsychotics in local 
communities did not decrease, but government agencies issued warnings about the 
association of these drugs with risk of CVA13.   
The use of population-based administrative data for research has several 
advantages. It consists of large patient cohorts and different quality metrics11. Data 
is collected for different types of healthcare providers, such as primary care, 
hospital care, and pharmacy data10. These databases can be linked together to study 
trends in outcomes and patients can be followed up for a long period of time. By 
means of hospital administrative data, when a patient is admitted to hospital, the 
cost for the whole cycle of care can be assessed, which includes diagnosis, 
investigations, management, length of stay and discharge plan22. Administrative 
data has also been used to assess other clinically relevant factors that impact 
outcomes of dementia23. 
It was important and relevant to clinical decision-making to conduct meta-
analysis that directly compared risk of CVA between first- and second-generation 
antipsychotic prescribing in dementia. The use of typical antipsychotics had not 
been associated with risk of CVA contrary to atypical antipsychotics13. The review 
has suggested that the use of atypical antipsychotics is as safe as typical 
antipsychotics. Previous incidence of CVA mentioned in clinical trials was very 
low15. The pooling of data from population-based studies provided significant 
number of cases of CVA in antipsychotic users to compare risk in different 
antipsychotic groups in a hope to prevent sampling bias. Since there was very 
limited number of population-based studies that directly compared risk of CVA 
between atypical antipsychotic users and those not taking any antipsychotics13, 15, 
the systematic review was primarily focused on comparing atypical and typical 
antipsychotic groups.  Once more data is available, more research is warranted into 
comparison of risk of CVA in atypical antipsychotic group and non-users.  
The studies included in the review have several limitations. There is still 
paucity of data to directly compare different groups of antipsychotics. Our meta-
analysis was based on data collected from only 5 studies. The studies were 
potentially prone to selection bias because patients using multiple antipsychotics 
and those who died during follow-up were excluded from the studies. Analyses 
included all kinds of dementia, while the adverse effect of antipsychotics may vary 
according to the type of dementia. The risk of CVA is further related to other lifesytle 
health behaviours like smoking, BMI, and physical activity; none of those variables 
were recorded in the administrative databases, and so could not be explicitly 
controlled for31. It was also difficult to ascertain the duration and dose of 
antipsychotics used, as previous studies have shown that the adverse events of the 
medications were dose dependent10. Results from the analysis cannot be used to 
identify association between antipsychotics and specific type of stroke as most 
studies pooled all types of stroke – ischaemic and haemorrhagic – when comparing 
adverse events of different kinds of antipsychotics. However, Barnett et al 
performed subgroup analysis on different kinds of dementia and found atypical 
antipsychotics to have relatively low risk of CVA compared to typical antipsychotics 
in vascular dementia patients.  
In conclusion, the results from meta-analysis suggest that the use of atypical 
antipsychotics was not associated with significant increased risk of CVA compared 
to typical antipsychotics based on population-based data. Future research should 
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